Tag: listing

All amounts in Canadian dollars unless otherwise stated.

Not for distribution to U.S. newswire services nor for dissemination to the United States
All amounts in Canadian dollars

BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,900 shares of Vor Bio’s common stock to 10 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).        

Growing SHOP Acquisition Pipeline
Addition to the Russell 2000 and 3000 Indexes
Presentation at Nareit’s REITweek 2026 Investor Conference

Seasoned international finance leader to support Kyivstar’s continued growth and digital transformation

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Enigmatig Limited (NYSE American: EGG) (“Enigmatig” or the “Company”), a global business enabler empowering small and medium-sized enterprises (SMEs) to scale across borders, today rang the Closing Bell at the New York Stock Exchange (“NYSE”) to mark its recent listing and reaffirm its mission to power the global ambitions of bold, forward-thinking businesses.

GREENWICH, Conn., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Associated Capital Group, Inc. (NYSE: AC) (“AC” or the “Company”) announced today that it has given formal notice to the New York Stock Exchange (“NYSE”) of its intention to voluntarily delist its Class A common stock (the “common stock”) from the NYSE and to deregister under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”). Following the de-listing from the NYSE, we expect to provide liquidity to AC’s Class A stock shareholders by listing AC Class A on the OTCQX platform (the “OTCQX”). AC plans on filing a Form 25 with the U.S. Securities and Exchange Commission (the “SEC”) on or about August 25, 2025. The last day of trading in AC’s common stock on the NYSE will be on or about September 4, 2025, when the Form 25 takes effect. Ninety days thereafter, AC’s common stock deregistration is expected to become effective. When AC files Form 15 on or about September 4, 2025, its filing obligations under the Exchange Act will immediately be suspended or terminated, including the filing of all reports on Forms 8-K, 10-Q and 10-K.

Offering Structured to Accelerate Streamex’s Operational Build-Out, Strategically Allocated with No Warrants

Guangzhou, China, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Youxin Technology Ltd (Nasdaq: YAAS) (the “Company” or “Youxin Technology”), a software as a service (“SaaS”) and platform as a service (“PaaS”) provider committed to helping retail enterprises digitally transform their businesses, today announced that it received two staff determination notices (the “Notice(s)”) from the Listings Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on August 13, 2025. The Notices notify the Company that it is not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, and pursuant to Listing Rule 5550(b)(2), it is required to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35 million for continued listing on the Nasdaq Capital Market (the “MVLS Requirement”).

New York, United States, Aug. 15, 2025 (GLOBE NEWSWIRE) --  Graphjet Technology (NADSAQ: GTI) (the “Company”) today announced that its board of directors (the “Board”) has determined the effective date for the previously approved share consolidation of the Company’s ordinary shares at a ratio of 1-for-60  and to reduce the par value of the Company’s ordinary shares from $0.0001 per share to $0.006 per share (the “Share Consolidation”).

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued inducement awards to Adam Craig, M.D., John Volpone and David Kirske under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”), consisting of (i) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 2,833,812 shares of X4’s common stock granted to Mr. Kirske. In addition, effective on August 14, 2025, the company issued additional inducement awards to Dr. Craig, Mr. Volpone and Mr. Kirske under the 2019 Inducement Plan, consisting of (i) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 352,800 shares of X4’s common stock granted to Mr. Kirske.

Transaction in Own Shares   

Landmark listing makes Kyivstar the first and only publicly listed pure-play Ukrainian investment opportunity in the U.S. Stock Markets